Details

Autor(en) / Beteiligte

• Feagan, Brian G
• Sandborn, William J
• Gasink, Christopher
• Jacobstein, Douglas
• Lang, Yinghua
• Friedman, Joshua R
• Blank, Marion A
• Johanns, Jewel
• Gao, Long-Long
• Miao, Ye
• Adedokun, Omoniyi J
• Sands, Bruce E
• Hanauer, Stephen B
• Vermeire, Severine
• Targan, Stephan
• Ghosh, Subrata
• de Villiers, Willem J
• Colombel, Jean-Frédéric
• Tulassay, Zsolt
• Seidler, Ursula
• Salzberg, Bruce A
• Desreumaux, Pierre
• Lee, Scott D
• Loftus, Edward V
• Dieleman, Levinus A
• Katz, Seymour
• Rutgeerts, Paul

Titel

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Ist Teil von

• The New England journal of medicine, 2016-11, Vol.375 (20), p.1946-1960

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• In two trials in patients with moderately to severely active Crohn's disease, intravenous ustekinumab was effective in those who did not have a response to conventional therapy or TNF antagonists. Subcutaneous ustekinumab was more effective than placebo in maintaining remission. Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract that is treated with glucocorticoids, immunosuppressants, tumor necrosis factor (TNF) antagonists, or integrin inhibitors. 1 – 3 The drawbacks of these agents include an increased risk of infection 4 – 7 and cancer 8 and limited efficacy. 9 Ustekinumab is a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23 that has been approved for use in the treatment of psoriasis and psoriatic arthritis. 10 In previous trials involving patients with psoriasis in which ustekinumab was administered subcutaneously for up to 5 years, the drug was not associated with an increased risk of serious adverse . . .